Market Research Logo

Global Antidepressant and Anti-Anxiety Drugs Market 2019-2029

Global Antidepressant and Anti-Anxiety Drugs Market 2019-2029

The global antidepressant and Anti-anxiety drugs market is estimated to have reached $12.16bn in 2018. In 2018, the SSRIs segment held 26% of the global antidepressant and anti-anxiety drugs market.

How this report will benefit you

Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 213-page report you will receive 73 tables and 92 figures– all unavailable elsewhere.

The 213-page report provides clear detailed insight into the global antidepressant and anti-anxiety drugs market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

  • Global antidepressant and anti-anxiety drugs market forecasts from 2019-2029
  • Our investigation shows forecasts to 2029 for the following submarket by drug class:
  • Serotonin Reuptake Inhibitors (SSRIs)
  • Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)
  • Atypical Antipsychotics
  • Tricyclic Antidepressants (TCAs)
  • Serotonin Antagonist and Reuptake Inhibitors (SARIs)
  • Benzodiazepines
  • Monoamine Oxidase Inhibitors (MAOIs)
  • Others
  • Our investigation shows forecasts to 2029 for the following submarket by indication:
  • Major Depressive Disorder (MDD)
  • General Anxiety Disorder (GAD)
  • Panic Disorder (PD)
  • Obsessive Compulsive Disorder (OCD)
  • Others
  • Our investigation shows forecasts to 2029 for the selected leading drugs:
  • Abilify
  • Abilify Maintena
  • Brintellix/Trintellix
  • Cipralex/Lexapro
  • Cymbalta
  • Invega Sustenna/ Xeplion/Trinza/Trevicta
  • Lamictal
  • Rexulti
  • Risperdal Consta
  • Zyprexa
  • This report provides individual revenue forecasts to 2029 for these regional and national markets:
  • North America: the US, Canada
  • Europe: the UK, Germany, Spain, France, Italy, Russia, Rest of Europe
  • Asia-Pacific: Japan, China, India, South Korea, Rest of Asia-Pacific
  • RoW: Brazil, Mexico, Russia, South Africa, Rest of RoW
  • This report also provides discussion and qualitative analysis on:
  • Factors that drive and restrain the global antidepressant and Anti-anxiety drugs market.
  • Antidepressant drugs pipeline analysis
  • Anti-anxiety drugs pipeline analysis
  • This report discusses the selected leading companies:
  • Allergan plc.
  • AstraZeneca plc.
  • Eli Lilly and Company
  • GlaxoSmithKline plc.
  • H. Lundbeck A/S
  • Johnson & Johnson
  • Otsuka Pharmaceutical Co., Ltd.
  • Pfizer Inc.
  • Pfizer Inc.
  • Takeda Pharmaceutical Company Ltd.
  • Valeant Pharmaceuticals
  • Key Questions Answered:
  • This report provides in-depth analysis of the antidepressant and anti-anxiety drugs market, identifying the latest trends and forecasting its growth and development over the coming 10 years.
  • The study addresses scope of the market in 2018 and assesses commercial drivers and restraints.
  • Through reading this report you will gain revenue forecasts from 2018 to 2029 for the overall world market and its leading submarkets, as well as regional and national markets.
  • This report provides revenue forecast for the leading antidepressant and anti-anxiety drugs from 2018 to 2019
  • Identify drug development trends that will affect market participants from 2018 to 2029.
  • See discussions of companies developing, manufacturing, and marketing antidepressant and ant-anxiety drugs, exploring products, technologies, R&D, partnerships, M&A and outlooks.
Visiongain’s study is intended for anyone requiring commercial analyses for the antidepressant and anti-anxiety drugs market. You find data, trends and predictions.

Please Note: Prior to initiating fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.

The publisher is using a password system to access all reports. Single user (non-printable) and departmental licenses expires after 12 month period. In the case of departmental site license purchases, the publisher requires all email addresses for the licensed users prior to fulfillment.


1. Report Overview
1.1 Overview of Findings
1.2 Why You Should Read This Report
1.3 How This Report Delivers
1.4 Main Questions Answered by This Analysis
1.5 Who is This Study For?
1.6 Research and Analysis Methods
1.7 Frequently Asked Questions (FAQs)
1.8 Associated Reports
1.9 About Visiongain
2. Introduction to Antidepressant and Anti-anxiety Drugs
2.1 Types of Depression and Anxiety Diseases
2.2 Prevalence and Mortality Profiles for Depression and Anxiety Diseases
2.3 Depression Contributing Factors and Prevention
2.4. History of Antidepressant and Anti-anxiety Drugs Development
2.5 Leading Classes of Antidepressant and Anti-anxiety Drugs
2.5.1 Selective serotonin reuptake inhibitors (SSRIs)
2.5.2 Serotonin-norepinephrine reuptake inhibitors (SNRIs)
2.5.3 Atypical Antipsychotics
2.5.4 Tricyclic antidepressants (TCAs)
2.5.5 Serotonin antagonist and reuptake inhibitors (SARIs)
2.5.6 Benzodiazepines
2.5.7 Monoamine Oxidase Inhibitors (MAOIs)
2.5.8 Other
3. Antidepressant and Anti-anxiety Drugs: World Market 2018-2029
3.1 Global Antidepressant and Anti-anxiety Drugs Revenues Plateau between 2014 and 2017
3.2 Antidepressant and Anti-anxiety Drugs - Market Segmentation
4. Antidepressant and Anti-anxiety Drugs Market by Drug Class 2018-2029
4.1 Selective serotonin reuptake inhibitors (SSRIs)
4.2 Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)
4.3 Atypical Antipsychotics
4.4 Tricyclic antidepressants (TCAs)
4.5 Serotonin Antagonist and Reuptake Inhibitors (SARIs)
4.6 Benzodiazepines
4.7 Monoamine Oxidase Inhibitors (MAOIs)
4.8 Other
5. Antidepressant and Anti-anxiety Drugs Market by Indication 2018-2029
5.1 Major Depressive Disorder (MDD)
5.2 Generalized Anxiety Disorder (GAD)
5.3 Panic Disorder (PD)
5.4 Obsessive Compulsive Disorder (OCD)
5.5 Others
6. Antidepressant and Anti-anxiety Drugs Market by Drug Type 2018-2029
6.1 Invega Sustenna/Xeplion/Trinza/Trevicta
6.2 LAMICTAL
6.3 RISPERDAL CONSTA
6.4 Cymbalta
6.5 ABILIFY MAINTENA
6.6 ABILIFY
6.7 Zyprexa
6.8 Rexulti
6.9 Brintellix/Trintellix
6.10 Cipralex/Lexapro
7. Drivers and Restraints in the Antidepressant and Anti-anxiety Drugs Market, 2018-2029
7.1. Market Drivers Analysis
7.1.1 Increasing Geriatric Population
7.1.2 Launch of New Drugs is Expected to Drive the Market Growth
7.1.3 Development of Advanced Antidepressant and Antianxiety Drugs
7.1.4 Increasing Prevalence of Depression and Anxiety
7.1.5 Escalating Mental Healthcare Awareness
7.2 Market Restraints Analysis
7.2.1 Social Stigma of Depression and Anxiety Diseases
7.2.2 Increase in Generic Competition
7.2.3 Stringent Regulatory Guidelines for New Drug Approval
8. Pipeline for Ant-depression and Anti-anxiety Drugs Market, 2018-2029
8.1 Antidepressant Drugs Pipeline Analysis
8.1.1 Esketamine
8.1.2 Rapastinel (GLYX-13)
8.1.3 SAGE-547
8.1.4 ALKS 5461
8.2 Anti-anxiety Drugs Pipeline Analysis
8.2.1 Aloradine (PH94B)
8.2.2 Tonmya (Cyclobenzaprine)
8.2.3 AVN-101
8.2.4 FKW00GA
8.2.5 JNJ-42165279
8.2.6 SRX246
8.2.7 Travivo (Gepirone ER)
8.2.8 Rexulti (Brexpiprazole)
8.2.9 NBTX-001 (Xenon)
9. The Leading National Markets 2018-2029
9.1 US and Europe Dominates the Global Antidepressant and Anti-anxiety Drugs Market
9.2 Above-Average Growth in Emerging Markets: Regional Forecasts 2018-2029
9.3 North America Antidepressant and Anti-anxiety Drugs Market
9.3.1 The US: Leading Market for Antidepressant and Anti-anxiety Drugs
9.3.1.1 The Antidepressant and Anti-anxiety Drugs Market in the U.S.
9.3.1.2 Continued Dominance of the U.S. Market
9.3.2 Canada Market Will Grow at High CAGR in North America Region
9.4 The European Union Forms Second Largest Regional Market
9.4.1 Increasing Prevalence of Chronic Diseases
9.4.2 EU5: Ageing Populations to Drive Market Growth
9.4.3 Germany is Leading the EU Antidepressant and Anti-anxiety Drugs Market
9.4.4 UK Market is Propelled by the Government Initiatives for Mental Health
9.4.5 France Antidepressant and Anti-anxiety Drugs is Projected to Grow at Lucrative CAGR
9.4.6 Italy is Expected Showcase Positive Growth
9.4.7 Spain Market is Projected to Grow at a Lucrative rate During 2018 - 2029
9.5 Asia-Pacific Antidepressant and Anti-anxiety Drugs is Fastest Growing Market
9.5.1 Japan – Still the Second Largest National Market
9.5.1.1 Is the government of Japan doing enough to raise awareness and to prevent suicide?
9.5.2 Chinese Antidepressant and Anti-anxiety Drugs Market
9.5.2.1 China’s Response: Major Efforts Over the Last Decade
9.5.3 Indian Market to Expand by Double Growth Over the Forecast Period
9.5.4 South Korean Market
9.6 RoW Nation Sales Still Expanding – Market Forecast 2018-2029
9.6.1 Brazilian Antidepressant and Anti-anxiety Drugs Market to Double in Size
9.6.2 Mexico Antidepressant and Anti-anxiety Drugs Sales - Forecast 2018-2029
9.6.3 Russia Antidepressant and Anti-anxiety Drugs
9.6.4 South Africa Antidepressant and Anti-anxiety Drugs
10. Leading Companies in the Antidepressant and Antianxiety Drugs Market
10.1 Johnson & Johnson
10.1.1 Business Overview
10.1.2 Financial Overview
10.1.3 Product Portfolio
10.1.4 Recent Developments (2014-2017)
10.1.5 SWOT Analysis
10.2. Pfizer Inc.
10.2.1 Business Overview
10.2.2 Financial Overview
10.2.3 Product Portfolio
10.2.5 SWOT Analysis
10.3. AstraZeneca
10.3.1 Business Overview
10.3.2 Financial Overview
10.3.3 Product Portfolio
10.3.4 Recent Developments
10.3.5 SWOT Analysis
10.4. Otsuka Pharmaceuticals
10.4.1 Business Overview
10.4.2 Financial Overview
10.4.3 Product Portfolio
10.4.4 Recent Developments (2014-2018)
10.4.5 SWOT Analysis
10.5. Eli Lilly & Co.
10.5.1 Business Overview
10.5.2 Financial Overview
10.5.3 Product Portfolio
10.5.4 Recent Developments 2018
10.5.5 SWOT Analysis
10.6. GlaxoSmithKline plc
10.6.1 Business Overview
10.6.2 Financial Overview
10.6.3 Product Portfolio
10.6.4 Recent Developments 2018
10.6.5 SWOT Analysis
10.7 H. Lundbeck A/S
10.7.1 Business Overview
10.7.2 Financial Overview
10.7.3 Product Portfolio
10.7.4 Recent Developments (2014-2018)
10.7.5 SWOT Analysis
10.8. Allergan plc
10.8.1 Business Overview
10.8.2 Financial Overview
10.8.3 Product Portfolio
10.8.4 Recent Developments (2014-2018)
10.8.5 SWOT Analysis
10.9. Takeda Pharmaceutical Company Limited
10.9.1 Business Overview
10.9.2 Financial Overview
10.9.3 Product Portfolio
10.9.4 Recent Developments (2014-2018)
10.9.5 SWOT Analysis
10.10. Bausch Health (Valeant Pharmaceuticals International)
10.10.1 Business Overview
10.10.2 Financial Overview
10.10.3 Product Portfolio
10.10.4 Recent Developments
10.10.5 SWOT Analysis
11. Qualitative Analysis of the Antidepressant and Anti-anxiety Drugs Industry and Market, 2018
11.1 SWOT Analysis: Strengths, Weaknesses, Opportunities and Threats
11.2 STEP Analysis: Social, Technological, Economic and Political Forces Affecting the Antidepressant and Anti-anxiety Drugs Market
11.2.1 Social Factors
11.2.2 Technological Developments
11.2.3 Economic Pressures
11.2.4 Political Issues
12. Antidepressant and Anti-anxiety Drugs Market –2018-2029: Conclusions
12.1 Blockbuster Antidepressant and Anti-anxiety Drugs in 2018 - Leading Brands
12.2 The Leading Drug Class of Antidepressant and Anti-anxiety Drugs in 2018 and 2029
12.3 Antidepressant and Anti-anxiety Drugs – Regional Market Changes
Associated Visiongain Reports
Visiongain Report Sales Order Form
About Visiongain
Visiongain report evaluation form
List of Tables
Table 2.1 Common Depression and Anxiety Diseases and Their Causes
Table 3.1 Antidepressant and Anti-anxiety Drugs: Historic Global Market Size ($bn), Annual Growth (%), and CAGR (%), 2014-2017
Table 4.1 Global Antidepressant and Anti-anxiety Drugs Market by Drug Class: Market Size ($bn) and Share (%), 2018
Table 4.2 Global Antidepressant and Anti-anxiety Drugs Market: Revenue Forecasts by Drug Class ($bn), Annual Growth (%) and CAGR, 2018-2029
Table 5.1 Global Antidepressant and Anti-anxiety Drugs Market by Indication: Market Size ($bn) and Share (%), 2018
Table 5.2 Global Antidepressant and Anti-anxiety Drugs Market: Revenue Forecasts by Indication ($bn), Annual Growth (%) and CAGR, 2018-2029
Table 6.1 Global Antidepressant and Anti-anxiety Drugs Market by Drug: Market Size ($bn) and Share (%), 2018
Table 6.2 Global Antidepressant and Anti-anxiety Drugs Market: Revenue Forecasts by Drug ($bn), Annual Growth (%) and CAGR, 2018-2029
Table 8.1 Pipeline of Antidepressant Drugs – Phase III, 2017
Table 8.2 Pipeline of Antidepressant Drugs – Phase II, 2017
Table 8.3 Pipeline of Antidepressant Drugs – Phase II, 2017
Table 8.4 Pipeline of Antidepressant Drugs – Phase I, 2017
Table 8.5 Pipeline of Leading Anti-anxiety Drugs, 2017
Table 9.1 Antidepressant and Anti-anxiety Drugs Sales by National and Regional Markets: Market Size ($bn) and Share (%), 2018
Table 9.2 North America Antidepressant and Anti-anxiety Drugs Market: Revenue Forecasts by Country ($bn), Annual Growth (%) and CAGR, 2018-2029
Table 9.3 North America Antidepressant and Anti-anxiety Drugs Market: Revenue Forecasts by Drug Class ($bn), Annual Growth (%) and CAGR, 2018-2029
Table 9.4 North America Antidepressant and Anti-anxiety Drugs Market: Revenue Forecasts by Indication ($bn), Annual Growth (%) and CAGR, 2018-2029
Table 9.5 U.S. Antidepressant and Anti-anxiety Drugs Market: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2018-2029
Table 9.6 Canada Antidepressant and Anti-anxiety Drugs Market: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2018-2029
Table 9.7 Europe Antidepressant and Anti-anxiety Drugs Market: Revenue Forecasts by Country ($bn), Annual Growth (%) and CAGR, 2018-2029
Table 9.8 Europe Antidepressant and Anti-anxiety Drugs Market: Revenue Forecasts by Drug Class ($bn), Annual Growth (%) and CAGR, 2018-2029
Table 9.9 Europe Antidepressant and Anti-anxiety Drugs Market: Revenue Forecasts by Indication ($bn), Annual Growth (%) and CAGR, 2018-2029
Table 9.10 Germany Antidepressant and Anti-anxiety Drugs Market: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2018-2029
Table 9.11 UK Antidepressant and Anti-anxiety Drugs Market: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2018-2029
Table 9.12 France Antidepressant and Anti-anxiety Drugs Market: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2018-2029
Table 9.13 Italy Antidepressant and Anti-anxiety Drugs Market: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2018-2029
Table 9.14 Spain Antidepressant and Anti-anxiety Drugs Market: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2018-2029
Table 9.15 Asia-Pacific Antidepressant and Anti-anxiety Drugs Market: Revenue Forecasts by Country ($bn), Annual Growth (%) and CAGR, 2018-2029
Table 9.16 Asia-Pacific Antidepressant and Anti-anxiety Drugs Market: Revenue Forecasts by Drug Class ($bn), Annual Growth (%) and CAGR, 2018-2029
Table 9.17 Asia Pacific Antidepressant and Anti-anxiety Drugs Market: Revenue Forecasts by Indication ($bn), Annual Growth (%) and CAGR, 2018-2029
Table 9.18 Japan Antidepressant and Anti-anxiety Drugs Market: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2018-2029
Table 9.19 China Antidepressant and Anti-anxiety Drugs Market: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2018-2029
Table 9.20 Indian Antidepressant and Anti-anxiety Drugs Market: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2018-2029
Table 9.21 South Korea Antidepressant and Anti-anxiety Drugs Market: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2018-2029
Table 9.22 Rest of the World Antidepressant and Anti-anxiety Drugs Market: Revenue Forecasts by Country ($bn), Annual Growth (%) and CAGR, 2018-2029
Table 9.23 Rest of the World Antidepressant and Anti-anxiety Drugs Market: Revenue Forecasts by Drug Class ($bn), Annual Growth (%) and CAGR, 2018-2029
Table 9.24 Rest of the World Antidepressant and Anti-anxiety Drugs Market: Revenue Forecasts by Indication ($bn), Annual Growth (%) and CAGR, 2018-2029
Table 9.25 Brazilian Antidepressant and Anti-anxiety Drugs Market: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2018-2029
Table 9.26 Mexico Antidepressant and Anti-anxiety Drugs Market: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2018-2029
Table 9.27 Russia Antidepressant and Anti-anxiety Drugs Market: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2018-2029
Table 9.28 South Africa Antidepressant and Anti-anxiety Drugs Market: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2018-2029
Table 10.1 Johnson & Johnson: Overview
Table 10.2 Johnson & Johnson: Product Portfolio
Table 10.3 Johnson & Johnson: Recent Developments
Table 10.4 Johnson & Johnson: Merger & Acquisition
Table 10.5 Pfizer Inc.: Overview
Table 10.6 Pfizer Inc.: Product Portfolio
Table 10.7 AstraZeneca: Overview
Table 10.8 AstraZeneca: Product Portfolio
Table 10.9 AstraZeneca: Recent Developments
Table 10.10 Otsuka: Overview
Table 10.11 Otsuka: Product Portfolio
Table 10.12 Otsuka: Recent Developments
Table 10.13 Lilly: Overview
Table 10.14 Lilly: Product Portfolio
Table 10.15 Lilly: Recent Developments
Table 10.16 GlaxoSmithKline: Overview
Table 10.17 GlaxoSmithKline: Product Portfolio
Table 10.18 GlaxoSmithKline: Recent Developments
Table 10.19 H. Lundbeck: Overview
Table 10.20 H. Lundbeck: Product Portfolio
Table 10.21 H. Lundbeck: Recent Developments
Table 10.22 H. Lundbeck: Strategic Collaboration
Table 10.23 Allergan: Overview
Table 10.24 Allergan: Product Portfolio
Table 10.25 Allergan: Recent Developments
Table 10.26 Takeda Pharmaceutical: Overview
Table 10.27 Takeda Pharmaceutical: Product Portfolio
Table 10.28 Takeda Pharmaceutical: Recent Developments
Table 10.27 Bausch Health: Recent Developments
Table 10.28 Bausch Health: Product Portfolio
Table 10.29 Bausch Health: Recent Developments
Table 11.1 Social, Technological, Economic, and Political Factors Affecting the Antidepressant and Anti-anxiety Drugs Market, 2018-2029

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report